Citius Pharmaceuticals to Feature Updated Positive Interim Results of i-MSC Study During Poster Presentation at International Society for Cell and Gene Therapy

 

Source:  Citius Pharmaceuticals,Inc. 5/18/2021

Poster to highlight positive safety and efficacy signals demonstrated in ongoing proof-of-concept large animal study evaluating i-MSC stem cell therapy in acute lung injury

Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on anti-infective products in adjunct cancer care, unique prescription products and stem cell therapy, today announced that it will present a poster at the International Society for Cell and Gene Therapy (ISCT) Annual Meeting, to be held virtually May 26-28, 2021.

Dr. Perenlei Enkhbaatar, Professor and Director of the Translational Intensive Care Unit at The University of Texas Medical Branch, will present a poster describing interim results of a proof-of-concept study evaluating the efficacy and safety of novel induced pluripotent stem cell-derived mesenchymal stem cells (i-MSCs) in a clinically relevant conscious ovine model of acute lung injury.

Posters will be available starting on May 25, 2021, a pre-conference day dedicated to poster presentations.

Abstract Title:	"Novel Induced-Mesenchymal Stem Cells (i-MSCs) Attenuate Severity of ARDS in Septic Sheep"
Authors:	K. Hashimoto, N. Bazhanov, P. Enkhbaatar, M. Angel, A. Lader, M. Czuczman, and M. Matthay
Abstract Number:	100
Date and Time:	May 25, 2021
Session I	12:30 – 2:00 PM EDT
Session II	8:00 – 9:30 PM EDT

"We are encouraged by the positive safety and efficacy signals of i-MSCs, as outlined in the reported interim results of our sheep study. Acute respiratory distress syndrome (ARDS) is a serious and life-threatening condition for which there are no FDA-approved therapies. In future studies, our goal is to increase the sample size and investigate mechanistic pathways. These findings should provide important information in the development of a planned future human clinical trial in ARDS patients. We believe in the potential of our i-MSCs to offer a meaningful option for those suffering from ARDS," stated Dr. Czuczman, Chief Medical Officer and Executive Vice President of Citius Pharmaceuticals, Inc.

The poster will be available to conference attendees via the conference website. The poster will be available on Citius' website once the event commences.

About Acute Respiratory Distress Syndrome (ARDS)

ARDS is an inflammatory process leading to build-up of fluid in the lungs and respiratory failure. It can occur due to infection, trauma and inhalation of noxious substances. ARDS accounts for approximately 10% of all ICU admissions and almost 25% of patients requiring mechanical ventilation. Survivors of ARDS are often left with severe long-term illness and disability. ARDS is a frequent complication of patients with COVID-19. ARDS is sometimes initially diagnosed as pneumonia or pulmonary edema (fluid in the lungs from heart disease). Symptoms of ARDS include shortness of breath, rapid breathing and heart rate, chest pain (particularly while inhaling), and bluish skin coloration. Among those who survive ARDS, a decreased quality of life is relatively common.

About Citius Pharmaceuticals, Inc.

Citius is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapy. The Company's lead product candidate, Mino-Lok^®, an antibiotic lock solution for the treatment of patients with catheter-related bloodstream infections (CRBSIs), is currently enrolling patients in a Phase 3 pivotal superiority trial.  Mino-Lok® was granted Fast Track designation by the U.S. Food and Drug Administration (FDA). Through its subsidiary, NoveCite, Inc., Citius is developing a novel proprietary mesenchymal stem cell treatment derived from induced pluripotent stem cells (iPSCs) for acute respiratory conditions, with a near-term focus on Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19.  For more information, please visit www.citiuspharma.com.